SEC Form 4 · accession 0001012975-15-000491
Oxford Immunotec Global PLC · OXFD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Dennis Henner
10% Owner
Nicholas Galakatos
10% Owner
Robert Liptak
10% Owner
Kurt Wheeler
10% Owner
Nicholas Simon
10% Owner
Clarus Ventures I, LLC
10% Owner
Clarus Lifesciences I, L.P.
10% Owner
Clarus Ventures I Management, L.P.
10% Owner
Period of report
Jun 15, 2015
Accepted (ET)
Jun 17, 2015 · 4:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Jun 15, 2015 | S | 1,529 | $14.27 | D | 2,277,078 | D | |
| Ordinary SharesF3,F2 | Jun 16, 2015 | S | 39,701 | $14.30 | D | 2,237,377 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $14.25 to $14.33 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2Securities held of record by Clarus Lifesciences I, L.P. ("Clarus"). Clarus Ventures I Management, L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. Clarus Ventures I, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Simon and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of the GPLP, GPLLC and Messrs. Galakatos, Henner, Liptak, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which it or he, as applicable, does not have an actual pecuniary interest.
- F3The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $14.25 to $14.67 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.